Ishikawa N, Endo Y, Sasaki T
Department of Experimental Therapeutics, Cancer Research Institute, Kanazawa University, Japan.
Jpn J Cancer Res. 1996 May;87(5):480-7. doi: 10.1111/j.1349-7006.1996.tb00249.x.
We examined mRNA expressions of urokinase-type plasminogen activator (u-PA), its specific receptor (u-PR), and plasminogen activator inhibitors (PAI-1 and PAI-2) in 50 human breast cancers by the reverse transcriptase-polymerase chain reaction method. The expressions of the genes are discussed in relation to the clinicopathological findings. In the overall population in breast cancers, a low level of PAI-2 expression was significantly associated with lymph node involvement (P < 0.0001). The u-PA, u-PR, and PAM expressions tended to be at high levels in such metastatic cancers. Also, positive expression of u-PA, u-PR, and PAI-1 was significantly correlated with negative expression of PAI-2. These results indicate that PAI-2 may play a critical role in the regulation of extracellular matrix degradation during tumor cell invasion and metastasis, and the expression of PAI-2 may be useful as a marker to evaluate the prognosis of breast cancers.
我们采用逆转录-聚合酶链反应方法检测了50例人类乳腺癌组织中尿激酶型纤溶酶原激活剂(u-PA)、其特异性受体(u-PR)以及纤溶酶原激活剂抑制剂(PAI-1和PAI-2)的mRNA表达情况。并结合临床病理结果对这些基因的表达进行了讨论。在乳腺癌总体人群中,PAI-2低水平表达与淋巴结受累显著相关(P < 0.0001)。在这类转移性癌中,u-PA、u-PR和PAI-1的表达往往处于高水平。此外,u-PA、u-PR和PAI-1的阳性表达与PAI-2的阴性表达显著相关。这些结果表明,PAI-2可能在肿瘤细胞侵袭和转移过程中细胞外基质降解的调节中起关键作用,PAI-2的表达可能作为评估乳腺癌预后的一个标志物。